Cargando…

Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study

BACKGROUND: COVID-19, an infectious disease caused by SARS-CoV-2, was shown to be associated with an increased risk of new-onset diabetes. Mechanisms contributing to the development of hyperglycemia are still unclear. We aimed to study whether hyperglycemia is related to insulin resistance and/or be...

Descripción completa

Detalles Bibliográficos
Autores principales: Gojda, Jan, Koudelková, Kateřina, Ouřadová, Anna, Lang, Alexander, Krbcová, Magdaléna, Gvozdeva, Alexandra, Šebo, Viktor, Slagmolen, Lotte, Potočková, Jana, Tůma, Petr, Rossmeislová, Lenka, Anděl, Michal, Karpe, Fredrik, Schlesinger, Sabrina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352285/
https://www.ncbi.nlm.nih.gov/pubmed/37460458
http://dx.doi.org/10.1038/s41387-023-00241-7
_version_ 1785074479150399488
author Gojda, Jan
Koudelková, Kateřina
Ouřadová, Anna
Lang, Alexander
Krbcová, Magdaléna
Gvozdeva, Alexandra
Šebo, Viktor
Slagmolen, Lotte
Potočková, Jana
Tůma, Petr
Rossmeislová, Lenka
Anděl, Michal
Karpe, Fredrik
Schlesinger, Sabrina
author_facet Gojda, Jan
Koudelková, Kateřina
Ouřadová, Anna
Lang, Alexander
Krbcová, Magdaléna
Gvozdeva, Alexandra
Šebo, Viktor
Slagmolen, Lotte
Potočková, Jana
Tůma, Petr
Rossmeislová, Lenka
Anděl, Michal
Karpe, Fredrik
Schlesinger, Sabrina
author_sort Gojda, Jan
collection PubMed
description BACKGROUND: COVID-19, an infectious disease caused by SARS-CoV-2, was shown to be associated with an increased risk of new-onset diabetes. Mechanisms contributing to the development of hyperglycemia are still unclear. We aimed to study whether hyperglycemia is related to insulin resistance and/or beta cell dysfunction. MATERIALS AND METHODS: Survivors of severe COVID-19 but without a known history of diabetes were examined at baseline (T0) and after 3 (T3) and 6 (T6) months: corticosteroids use, indirect calorimetry, and OGTT. Insulin response and sensitivity (IS) were expressed as insulinogenic (IGI), disposition (DI), and Matsuda insulin sensitivity index (ISI). Resting energy expenditure (REE) and respiratory quotient (RQ) was calculated from the gas exchange and nitrogen losses. RESULTS: 26 patients (out of 37) with complete outcome data were included in the analysis (age ~59.0 years; BMI ~ 30.4, 35% women). Patients were hypermetabolic at T0 (30.3 ± 4.0 kcal/kg lean mass/day, ~120% predicted) but REE declined over 6 months (ΔT6-T0 mean dif. T6-T0 (95% CI): −5.4 (−6.8, −4.1) kcal/kg FFM/day, p < 0.0001). 17 patients at T0 and 13 patients at T6 had hyperglycemia. None of the patients had positive islet autoantibodies. Insulin sensitivity in T0 was similarly low in hyperglycemic (H) and normoglycemic patients (N) (T0 ISI(H) = 3.12 ± 1.23, ISI(N) = 3.47 ± 1.78, p = 0.44), whereas insulin response was lower in the H group (DI(H) = 3.05 ± 1.79 vs DI(N) = 8.40 ± 5.42, p = 0.003). Over 6 months ISI (ΔT6-T0 mean dif. T6-T0 for ISI (95% CI): 1.84 (0.45, 3.24), p = 0.01)) increased in the H group only. CONCLUSIONS: Patients with severe COVID-19 had increased REE and insulin resistance during the acute phase due to the infection and corticosteroid use, but these effects do not persist during the follow-up period. Only patients with insufficient insulin response developed hyperglycemia, indicating that beta cell dysfunction, rather than insulin resistance, was responsible for its occurrence.
format Online
Article
Text
id pubmed-10352285
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-103522852023-07-19 Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study Gojda, Jan Koudelková, Kateřina Ouřadová, Anna Lang, Alexander Krbcová, Magdaléna Gvozdeva, Alexandra Šebo, Viktor Slagmolen, Lotte Potočková, Jana Tůma, Petr Rossmeislová, Lenka Anděl, Michal Karpe, Fredrik Schlesinger, Sabrina Nutr Diabetes Article BACKGROUND: COVID-19, an infectious disease caused by SARS-CoV-2, was shown to be associated with an increased risk of new-onset diabetes. Mechanisms contributing to the development of hyperglycemia are still unclear. We aimed to study whether hyperglycemia is related to insulin resistance and/or beta cell dysfunction. MATERIALS AND METHODS: Survivors of severe COVID-19 but without a known history of diabetes were examined at baseline (T0) and after 3 (T3) and 6 (T6) months: corticosteroids use, indirect calorimetry, and OGTT. Insulin response and sensitivity (IS) were expressed as insulinogenic (IGI), disposition (DI), and Matsuda insulin sensitivity index (ISI). Resting energy expenditure (REE) and respiratory quotient (RQ) was calculated from the gas exchange and nitrogen losses. RESULTS: 26 patients (out of 37) with complete outcome data were included in the analysis (age ~59.0 years; BMI ~ 30.4, 35% women). Patients were hypermetabolic at T0 (30.3 ± 4.0 kcal/kg lean mass/day, ~120% predicted) but REE declined over 6 months (ΔT6-T0 mean dif. T6-T0 (95% CI): −5.4 (−6.8, −4.1) kcal/kg FFM/day, p < 0.0001). 17 patients at T0 and 13 patients at T6 had hyperglycemia. None of the patients had positive islet autoantibodies. Insulin sensitivity in T0 was similarly low in hyperglycemic (H) and normoglycemic patients (N) (T0 ISI(H) = 3.12 ± 1.23, ISI(N) = 3.47 ± 1.78, p = 0.44), whereas insulin response was lower in the H group (DI(H) = 3.05 ± 1.79 vs DI(N) = 8.40 ± 5.42, p = 0.003). Over 6 months ISI (ΔT6-T0 mean dif. T6-T0 for ISI (95% CI): 1.84 (0.45, 3.24), p = 0.01)) increased in the H group only. CONCLUSIONS: Patients with severe COVID-19 had increased REE and insulin resistance during the acute phase due to the infection and corticosteroid use, but these effects do not persist during the follow-up period. Only patients with insufficient insulin response developed hyperglycemia, indicating that beta cell dysfunction, rather than insulin resistance, was responsible for its occurrence. Nature Publishing Group UK 2023-07-17 /pmc/articles/PMC10352285/ /pubmed/37460458 http://dx.doi.org/10.1038/s41387-023-00241-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Gojda, Jan
Koudelková, Kateřina
Ouřadová, Anna
Lang, Alexander
Krbcová, Magdaléna
Gvozdeva, Alexandra
Šebo, Viktor
Slagmolen, Lotte
Potočková, Jana
Tůma, Petr
Rossmeislová, Lenka
Anděl, Michal
Karpe, Fredrik
Schlesinger, Sabrina
Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study
title Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study
title_full Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study
title_fullStr Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study
title_full_unstemmed Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study
title_short Severe COVID-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study
title_sort severe covid-19 associated hyperglycemia is caused by beta cell dysfunction: a prospective cohort study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10352285/
https://www.ncbi.nlm.nih.gov/pubmed/37460458
http://dx.doi.org/10.1038/s41387-023-00241-7
work_keys_str_mv AT gojdajan severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT koudelkovakaterina severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT ouradovaanna severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT langalexander severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT krbcovamagdalena severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT gvozdevaalexandra severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT seboviktor severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT slagmolenlotte severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT potockovajana severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT tumapetr severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT rossmeislovalenka severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT andelmichal severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT karpefredrik severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy
AT schlesingersabrina severecovid19associatedhyperglycemiaiscausedbybetacelldysfunctionaprospectivecohortstudy